HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival

Bookmark and Share
Published: 7 Dec 2017
Views: 1529
Dr Louis Fehrenbacher - Kaiser Permanente Vallejo Medical Center, California, USA

Dr Fehrenbacher speaks with ecancer at SABCS 2017 about a phase III trial of adjuvant chemotherapy with or without trastuzumab for HER2low invasive breast cancer.

Building on findings for high HER2 patients, Dr Fehrenbacher sets out the rationale for investigating HER2 low and negative patients, as scored by FISH or IHC.
Ultimately, trial findings were negative, with trastuzumab offering no improvement for invasive disease free survival.

Watch the press conference for more.